SOMOSA: Study of Mechanisms of Action of Omalizumab in Severe Asthma. 1st March 2016

A study led by the University of Southampton has been initiated involving the Sheffield Severe Asthma service, Principal Investigator Prof Ian Sabroe, the Respiratory Physiology department and the Clinical Research Facility. In this study we are recruiting patients who will be receiving treatment with the asthma medication Xolair (omalizumab) as part of their normal care. Xolair is currently licenced in the UK to treat patients with severe asthma but it is clear that not everyone with severe asthma will benefit from treatment. The data collected from the study of samples and other tests may enable researchers to predict which patients will benefit from Xolair and which patients will not, so that treatment can be given to patients more efficiently and effectively.

For further information contact